Wechselwirkungen · Eviplera
Eviplera 200 mg/25 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–11
HOS-214377 · Präparat HOS-155326
10 Medicinal product by therapeutic Effects on medicinal product Recommendation concerning areas levels. co-administration with Eviplera Mean percent change in AUC, Cmax, Cmin Protease inhibitors (PIs) - boosted (with co-administration of low-dose ritonavir) Atazanavir/Ritonavir/Emtricitabine Interaction not studied. Concomitant use of Eviplera with Atazanavir/Ritonavir/Rilpivirine Interaction not studied. ritonavir-boosted PIs causes an Atazanavir (300 mg once daily)/ Atazanavir: increase in the plasma Ritonavir (100 mg once daily)/ AUC: ↓ 25% concentrations of rilpivirine Tenofovir disoproxil (245 mg once Cmax: ↓ 28% (inhibition of CYP3A enzymes). daily) Cmin: ↓ 26% No dose adjustment is required. Tenofovir: AUC: ↑ 37% Cmax: ↑ 34% Cmin: ↑ 29% Darunavir/Ritonavir/Emtricitabine Interaction not studied. Darunavir (800 mg once daily)/ Darunavir: Ritonavir (100 mg once daily)/ AUC: ↔ Rilpivirine1 Cmin: ↓ 11% Cmax: ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) atazanavir (HOS-086180) protease (HOS-085623) darunavir (HOS-086181) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-06-19T11:57:00Z · SHA-256 3873fd554f54608c25be65a5e155834d2d4981603221b5f24abb68e92e1af40e · Passage 75d0183f6690adb6491f48168e28243f726e2f5cfc44ec15f1ac26eb41136d46 · Zeichen 7266–8826 im Abschnitt